^
Association details:
| Biomarker: | EGF expression |
|---|---|
| Cancer: | Tongue Carcinoma |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells
Excerpt:
Our data suggest that the amount of EGF is a determinant of the tumor cell proliferation rate and the response to cetuximab treatment in tongue cancer. Thus, EGF is a potential predictive biomarker of poor cetuximab response and a possible treatment target.
DOI:
10.1111/jop.12310
